Advertisement

Topics

French Biotech fails Second Phase II Trial for Cardiovascular Disease

07:18 EDT 20 Mar 2017 | Labiotech.eu

Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular and metabolic diseases. The company now presented data on its lead candidate ...

This awesome article French Biotech fails Second Phase II Trial for Cardiovascular Disease appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: French Biotech fails Second Phase II Trial for Cardiovascular Disease

NEXT ARTICLE

More From BioPortfolio on "French Biotech fails Second Phase II Trial for Cardiovascular Disease"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...